Orbitrap

Thermo Fisher Scientific Recognized by R&D 100 Awards for Innovations in Science and Technology

Retrieved on: 
Friday, September 8, 2023
Technology, Research, Medical Devices, Other Technology, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Vaccine, Hybrid vehicle, Multimedia, Thermo Fisher Scientific, Cell, Antibody, Proteomics, CTS, Thermo, Protein, Metabolomics, R, Centrifuge, Mindful Scientific Inc., Orbitrap, Fine chemical

Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards , honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards , honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.
  • “With a mission to enable our customers to make the world healthier, cleaner and safer, we’re committed to scientific advancement,” said Karen Nelson, chief scientific officer, Thermo Fisher Scientific.
  • Established in 1963, the R&D 100 Awards is the only science and technology awards competition that recognizes new commercial products, technologies and materials for their technological significance.
  • Sponsored by R&D World Magazine, the R&D 100 Awards recognize and celebrate the 100 most innovative technologies of the previous year.

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Retrieved on: 
Monday, July 24, 2023
Molecule, DNA, Francis Crick Institute, Cryogenic electron microscopy, Cancer, Research, Doctor of Philosophy, Death, Structure, Protein, Patient, Risk, RAD51, BRCA2, PARP, Breast cancer, Orbitrap, DNA repair, Medical imaging, Dietary supplement, Vaccine, Nature

The research, enabled by LUMICKS' C-Trap® dynamic single-molecule analysis technology, reveals new crucial insights into DNA repair mechanisms associated with cancer.

Key Points: 
  • The research, enabled by LUMICKS' C-Trap® dynamic single-molecule analysis technology, reveals new crucial insights into DNA repair mechanisms associated with cancer.
  • Breast cancer alone caused 685,000 deaths in 2020 and accounted for 12.5% of all cancer diagnoses.
  • The study provided novel insights into the role of RAD51BCD-XRCC2 complex (BCDX2) in DNA repair and cancer avoidance.
  • We now understand its crucial role in DNA repair, which explains why mutations can lead to cancer."

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Retrieved on: 
Monday, July 24, 2023
Molecule, DNA, Francis Crick Institute, Cryogenic electron microscopy, Cancer, Research, Doctor of Philosophy, Death, Structure, Protein, Patient, Risk, RAD51, BRCA2, PARP, Breast cancer, Orbitrap, DNA repair, Medical imaging, Dietary supplement, Vaccine, Nature

The research, enabled by LUMICKS' C-Trap® dynamic single-molecule analysis technology, reveals new crucial insights into DNA repair mechanisms associated with cancer.

Key Points: 
  • The research, enabled by LUMICKS' C-Trap® dynamic single-molecule analysis technology, reveals new crucial insights into DNA repair mechanisms associated with cancer.
  • Breast cancer alone caused 685,000 deaths in 2020 and accounted for 12.5% of all cancer diagnoses.
  • The study provided novel insights into the role of RAD51BCD-XRCC2 complex (BCDX2) in DNA repair and cancer avoidance.
  • We now understand its crucial role in DNA repair, which explains why mutations can lead to cancer."

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Retrieved on: 
Wednesday, June 7, 2023
Astral, Proteogenomics, Workflow, Mass spectrometry, Chromatography, Cancer, Proteome, Thermo Fisher Scientific, Genomics, Proteomics, Science, Plasma, Thermo, Area studies, Seer, IDS, SEER, Health, Disease, Orbitrap, Heating, ventilation, and air conditioning, Uranium mining

As part of the collaboration, Seer will establish the Seer Technology Access Center to showcase its latest product, the Proteograph XT Assay Kit, in combination with Thermo Fisher’s newest mass spectrometer, the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer (MS).

Key Points: 
  • As part of the collaboration, Seer will establish the Seer Technology Access Center to showcase its latest product, the Proteograph XT Assay Kit, in combination with Thermo Fisher’s newest mass spectrometer, the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer (MS).
  • The Seer Technology Access Center will address an important unmet need for researchers who do not have access to mass spectrometry, but wish to undertake deep unbiased proteomics studies, such as translational and genomics researchers performing population-scale studies with deep molecular profiling.
  • As part of the collaboration, Seer and Thermo Fisher will develop and optimize proteomics and proteogenomics workflows, including the integration of data and analysis protocols.
  • To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio.

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Retrieved on: 
Monday, June 5, 2023
Science, Other Science, Other Manufacturing, Finance, Professional Services, Technology, Manufacturing, Other Technology, Astral, American Society for Mass Spectrometry, University, ASMS, Mass spectrometry, George R. Brown Convention Center, Cardiovascular disease, Cancer, TMO, Proteomics, Proteome, Multimedia, Research, Thermo Fisher Scientific, Genomics, Biomarker, Thermo, Laboratory, University of Washington Department of Global Health, Medicine, Health, Mindful Scientific Inc., Society, NYSE, Disease, Medical imaging, Orbitrap

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.
  • Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230605005016/en/
    The Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer offers accurate and precise quantitation in proteomics laboratories with faster throughput, deeper coverage and higher sensitivity than the current state-of-the-art.
  • “The Orbitrap Astral mass spectrometer is a true gamechanger, offering an unrivaled combination of sensitivity, dynamic range and speed that doesn’t compromise accurate and precise quantitation.

MOBILion to Showcase Innovations in Separation Science - New Capabilities and Application Workflows at ASMS 2023

Retrieved on: 
Thursday, June 1, 2023
PTM, American Society for Mass Spectrometry, Structure, Glycoprotein, PFAS, ASMS, SLIM, Lipidomics, Mass spectrometry, Software, Booth, Lipid, Thermo Fisher Scientific, Doctor of Philosophy, Excipient, MOBIE, PerkinElmer, Agilent Technologies, Protein, LCMS, Lactoferrin, Poster, Society, Structures for lossless ion manipulations, Citrullination, Peptide, Orbitrap, Fine chemical

MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.

Key Points: 
  • MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.
  • In six seminar presentations, industry collaborators will present data demonstrating the unique ability to solve their analytical challenges with high-resolution ion mobility (HRIM-MS).
  • ASMS provides the perfect venue to share our latest advancements and foster collaborations that will drive innovation forward."
  • To obtain further details regarding MOBILion Systems' presence at ASMS 2023 and to register for the events, please visit: https://info.mobilionsystems.com/asms2023 .

MOBILion Systems Demonstrates Integration of SLIM Technology with Orbitrap Technology Yielding Sensitivity Gains

Retrieved on: 
Wednesday, January 11, 2023
Orbitrap, SLIM, Partnership, Peptide, Protein, World Congress, Thermo Fisher Scientific, 2000s, Human Proteome Organization, Ion, Lipid, Thermo, System, HUPO, Agilent Technologies, Proteomics, Video game console, Fine chemical

CHADDS FORD, Pa., Jan. 11, 2023 /PRNewswire/ -- MOBILion Systems, Inc., a life science tools and instrumentation company, presented at the Human Proteome Organization (HUPO) World Congress the first of its kind proof of concept integrating their SLIM (structures for lossless ion manipulation) technology with the Thermo Scientific™ Orbitrap Exploris™ 480 mass spectrometer.

Key Points: 
  • We are excited about the debut of this second iteration of SLIM technology to advance separation science.
  • A project involving MOBILion and Thermo Fisher aims to address the industry's current limitations in sensitivity, including challenges in detecting low abundance analytes.
  • MOBILion is proving its SLIM technology is a platform technology well-suited for customization, allowing it to be tuned to a variety of mass spectrometer platforms.
  • The early feedback from KOLs following the proof of concept integration with the Orbitrap platform has been overwhelmingly positive.

Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap Mass Spectrometry Imaging Platform

Retrieved on: 
Monday, June 6, 2022
Technology, Research, Other Technology, Biotechnology, Hardware, Health, Pharmaceutical, Other Science, Science, Science, Biomarker, Chromatography, Mindful Scientific Inc., Applied Biosystems, ASMS, Conference, Minneapolis, Research, Patheon, Society, 3D, Mass spectrometry, Minneapolis Convention Center, Invitrogen, American Society for Mass Spectrometry, PPD, MSI, Metabolomics, Glycomics, Proteomics, Lipidomics, Technology, AF, Fisher Scientific, Laboratory, Health, Thermo Fisher Scientific, Drug development, Tissue, West Pharmaceutical Services explosion, Orbitrap, AP, Peptide, SSH File Transfer Protocol, Medical imaging

ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, and TransMIT GmbH Center for Mass Spectrometric Developments have announced a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs.

Key Points: 
  • ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, and TransMIT GmbH Center for Mass Spectrometric Developments have announced a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs.
  • This co-marketing agreement will provide integrated solutions for mass spectrometry imaging, offering a label-free approach to map the distribution of a wide range of both known and unknown compounds directly sampled from biological tissue, said Jim Yano, senior director, life sciences mass spectrometry portfolio management, chromatography and mass spectrometry, Thermo Fisher Scientific.
  • Professor Bernhard Spengler, director, TransMIT Center for Mass Spectrometric Developments, said, Our AP-SMALDI5 AF ion source coupled with Thermo Fishers Orbitrap technology create an MSI platform for high spatial resolution along with high mass resolution and mass accuracy.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

LUMICKS Announces 100th Customer Placement of its C-Trap® Product

Retrieved on: 
Monday, March 14, 2022
Molecule, Molecular biology, Research, MRC Laboratory of Molecular Biology, Health, MRC, DNA, Sale, Orbitrap, Technology, Biology, Growth, New Family Structures Study, Disease, Division, CEO, Pharmaceutical industry

AMSTERDAM, March 14, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, today announced that it has completed installation and training for its 100th customer sale, marking an important milestone in the company's growth from a start-up in 2015. The installation of the LUMICKS' new C-Trap Edge® took place at the MRC Laboratory of Molecular Biology (MRC LMB) in Cambridge, United Kingdom.

Key Points: 
  • The installation of the LUMICKS' new C-Trap Edge took place at the MRC Laboratory of Molecular Biology (MRC LMB) in Cambridge, United Kingdom.
  • As we celebrate the 100th installation of our equipment, we are already working steadily to accelerate global sales and installations of our equipment throughout this year."
  • We welcome LUMICKS' C-Trap technology into our laboratory and we look forward to utilizing it in a wide range of research programs."
  • The technological advances embodied in LUMICKS' C-Trap technology have been lauded by researchers worldwide for their transformational role in advancing scientific discoveries.

LUMICKS Announces 100th Customer Placement of its C-Trap® Product

Retrieved on: 
Monday, March 14, 2022
Molecule, Molecular biology, Research, MRC Laboratory of Molecular Biology, Health, MRC, DNA, Sale, Orbitrap, Technology, Biology, Growth, New Family Structures Study, Disease, Division, CEO, Pharmaceutical industry

AMSTERDAM, March 14, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, today announced that it has completed installation and training for its 100th customer sale, marking an important milestone in the company's growth from a start-up in 2015. The installation of the LUMICKS' new C-Trap Edge® took place at the MRC Laboratory of Molecular Biology (MRC LMB) in Cambridge, United Kingdom.

Key Points: 
  • The installation of the LUMICKS' new C-Trap Edge took place at the MRC Laboratory of Molecular Biology (MRC LMB) in Cambridge, United Kingdom.
  • As we celebrate the 100th installation of our equipment, we are already working steadily to accelerate global sales and installations of our equipment throughout this year."
  • We welcome LUMICKS' C-Trap technology into our laboratory and we look forward to utilizing it in a wide range of research programs."
  • The technological advances embodied in LUMICKS' C-Trap technology have been lauded by researchers worldwide for their transformational role in advancing scientific discoveries.